Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 16, 2015 - Issue 17
Submit an article Journal homepage
343
Views
17
CrossRef citations to date
0
Altmetric
Drug Evaluations

Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use

JoAnn V PinkertonDepartment of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA22908, USACorrespondence[email protected]
&
Risa KaganDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco East Bay Physicians Medical Group affiliated with Sutter East Bay Medical Foundation, Berkeley, CA94704, USA
Pages 2703-2714 | Published online: 03 Dec 2015

Bibliography

  • Papers of special note have been highlighted as of considerable interest (••) to readers.
  • Barrett-Connor E, Laughlin GA. Endogenous and exogenous estrogen, cognitive function, and dementia in postmenopausal women: evidence from epidemiologic studies and clinical trials. Semin Reprod Med. 2009;27(3):275–282.
  • The North American Menopause Society (NAMS) 2013 symptomatic vulvovaginal atrophy advisory panel. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902.
  • Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133–2142.
  • Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5:437–447.
  • Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790–1799.
  • Wysocki S, Kingsberg S, Krychman M. Management of vaginal atrophy: implications from the REVIVE study. Clin Med Insights Reprod Health. 2014;8:23–30.
  • Nappi RE, Kingsberg S, Maamari R, et al. The CLOSER (CLarifying Vaginal Atrophy’s Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med. 2013;10(9):2232–2241.
  • Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063–1068.
  • Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21:924–932.
  • Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539.
  • Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87–94.
  • Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
  • Manson JE, Goldstein SR, Kagan R, et al. Why the product labeling for low-dose vaginal estrogen should be changed. Menopause. 2014;21(9):911–916.
  • Osphena™ (ospemifene). [prescribing information]. Florham Park (NJ): Shionogi, Inc; 2013.
  • Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA. 2003;289(24):3243–3253.
  • Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289(24):3254–3263.
  • Archer DF, Carr BR, Pinkerton JV, et al. Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause. 2015;22(7):786–796.
  • Unkila M, Kari S, Yatkin E, et al. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. J Steroid Biochem Mol Biol. 2013;138:107–115.
  • Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology. 2000;141(2):809–820.
  • Kangas L, Harkonen P, Vaananen K, et al. Effects of the selective estrogen receptor modulator ospemifene on bone in rats. Horm Metab Res. 2014;46(1):27–35.
  • Kangas L, Harkonen P, Vaananen K, et al. Effects of ospemifene on breast tissue morphology and proliferation: a comparative study versus other selective estrogen receptor modulators in ovariectomized rats. Horm Metab Res. 2014;46(5):328–332.
  • Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. 2001;77(4–5):271–279.
  • Soe LH, Wurz GT, Kao CJ, et al. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int J Womens Health. 2013;5:605–611.
  • Bachmann GA, Komi JO, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480–486.

••A key 12-week Phase III study evaluating the clinical efficacy of ospemifene in women with VVA.

  • Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20:623–630.

••A key paper describing the clinical efficacy of ospemifene in the dyspareunia stratum of a 12-week, Phase III

  • Portman D, Palacios S, Nappi RE, et al. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas. 2014;78(2):91–98.

••A key paper describing the clinical efficacy of ospemifene in the vaginal dryness stratum of a 12-week, Phase III 12-week study

  • Simon J, Portman D, Mabey RG Jr, et al. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas. 2014;77(3):274–281.

••A pivotal Phase III study evaluating the clinical safety of ospemifene

  • Simon JA, Lin VH, Radovich C, et al. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20(4):418–427.

••A pivotal Phase III study evaluating the clinical safety of ospemifene

  • Goldstein SR, Bachmann GA, Koninckx PR, et al. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173–182.

••A pivotal 52-week study evaluating the clinical efficacy and safety of ospemifene

  • Komi J, Heikkinen J, Rutanen EM, et al. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol. 2004;18(3):152–158.
  • Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab. 2006;24(4):314–318.
  • Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23(4):525–535.
  • Palacios S, Silverman SL, de Villiers TJ, et al. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause. 2015;22(8):806–813.
  • Harvey JA, Holm MK, Ranganath R, et al. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause. 2009;16(6):1193–1196.
  • Palacios S, de Villiers TJ, Nardone FC, et al. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas. 2013;76(1):81–87.
  • Kagan R, Williams RS, Pan K, et al. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens (BZA/CE) for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17(2):281–289.
  • Kangas L, Unkila M. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids. 2013;78(12–13):1273–1280.
  • Burich RA, Mehta NR, Wurz GT, et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause. 2012;19(1):96–103.
  • Evista®. [prescribing information]. Indianapolis (IN): Eli Lilly and Company; 2014.
  • Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab. 2000;85(6):2197–2202.
  • Meunier PJ, Vignot E, Garnero P, et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int. 1999;10(4):330–336.
  • Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–1834.
  • Cohen FJ, Watts S, Shah A, et al. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol. 2000;95(1):104–110.
  • Delmanto A, Nahas-Neto J, Nahas EA, et al. Effect of raloxifene on the vaginal epithelium of postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2008;139(2):187–192.
  • Novaldex®. [prescribing information]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2006.
  • Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326(13):852–856.
  • Friedrich M, Mink D, Villena-Heinsen C, et al. Tamoxifen and proliferation of vaginal and cervical epithelium in postmenopausal women with breast cancer. Eur J Obstet Gynecol Reprod Biol. 1998;80(2):221–225.
  • Pinkerton JV, Stanczyk FZ. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause. 2014;21(3):309–319.
  • Duavee®. [prescribing information]. Philadelphia (PA): Wyeth Pharmaceuticals Inc; 2013.
  • DeGregorio MW, Zerbe RL, Wurz GT. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids. 2014;90:82–93.
  • FDA Guidance for Industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms: recommendations for clinical evaluation. Rockford (MD): US Food and Drug Administration; 2003.
  • Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18(2):226–232.
  • Kagan R, Portman D, Archer DF, et al. Responder analysis of ospemifene treatment for vulvar and vaginal atrophy in postmenopausal women in phase 3 randomized, placebo-controlled in trials. Paper presented at: North American Menopause Society 25th Annual Meeting; 2014 Oct 15–18; Washington, DC.
  • Constantine G, Graham S, Koltun WD, et al. Assessment of ospemifene or lubricants on clinical signs of VVA. J Sex Med. 2014;11(4):1033–1041.
  • Goodman MP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Womens Health. 2012;21(2):161–169.
  • Constantine GD, Goldstein SR, Archer DF. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause. 2015;22(1):36–43.

••A post hoc analysis of Phase II and III endometrial safety data

  • Pinkerton JV, Archer DF, Graham S, et al. Effect of ospemifene on vasomotor symptoms in postmenopausal women. North American Menopause Society 25th Annual Meeting; 2014 Oct 14–18; Washington, DC.
  • Goldstein SR. Postmenopausal dyspareunia: has the Food and Drug Administration really helped? Menopause. 2013;20(6):596–597.
  • Goldstein SR, Neven P, Zhou L, et al. Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet Gynecol. 2001;98(1):91–96.
  • Vardy MD, Lindsay R, Scotti RJ, et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol. 2003;189(1):81–88.
  • Ismail SI, Bain C, Hagen S. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women. Cochrane Database Syst Rev. 2010;9:CD007063.
  • Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost. 2008;99(2):338–342.
  • De Villiers TJ. Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women. Climacteric. 2009;12(Suppl 1):108–111.
  • Senshio product information. South Wales: Penn Pharmaceutical Services Ltd; 2015.
  • Committee for Medicinal Products for Human Use (CHMP). Senshio summary of opinion. London: European Medicines Agency; 2014.
  • Baumgart J, Nilsson K, Evers AS, et al. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause. 2013;20(2):162–168.
  • Pinkerton JV, Shifren JL, La VJ, et al. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause. 2003;10(1):45–52.
  • Kaur G, Mahajan MP, Pandey MK, et al. Design, synthesis and evaluation of ospemifene analogs as anti-breast cancer agents. Eur J Med Chem. 2014;86:211–218.
  • Ellis AJ, Hendrick VM, Williams R, et al. Selective estrogen receptor modulators in clinical practice: a safety overview. Expert Opin Drug Saf. 2015;14(6):921–934.
  • Wurz GT, Soe LH, DeGregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas. 2013;74(3):220–225.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.